Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLCG1 | P19174 | 1/20 | 0.42 |
| ▸ | ELANE | P08246 | 7/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1198655 | 1.00 | PLCG1 (0.42) | PLCG1ELANERAB9ATDP1HTR2A | |
| SCHEMBL337697 | 1.00 | PLCG1 (0.42) | PLCG1ELANERAB9ATDP1HTR2A | |
| SCHEMBL14153496 | 1.00 | PLCG1 (0.42) | PLCG1ELANERAB9ATDP1HTR2A | |
| SCHEMBL407970 | 1.00 | PLCG1 (0.42) | PLCG1ELANERAB9ATDP1HTR2A | |
| SCHEMBL8695596 | 1.00 | PLCG1 (0.42) | PLCG1ELANERAB9ATDP1HTR2A | |
| SCHEMBL8924773 | 1.00 | PLCG1 (0.42) | PLCG1ELANERAB9ATDP1HTR2A | |
| SCHEMBL13483984 | 1.00 | PLCG1 (0.42) | PLCG1ELANERAB9ATDP1HTR2A | |
| SCHEMBL437737 | 1.00 | PLCG1 (0.42) | PLCG1ELANERAB9ATDP1HTR2A | |
| SCHEMBL18977837 | 0.94 | PLCG1 (0.40) | PLCG1ELANERAB9AHTT | |
| SCHEMBL10013149 | 0.94 | PLCG1 (0.42) | PLCG1ELANERAB9ATDP1HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093378-B2 | Crystallization method for intermediates of carbapenem antibiotics | KANEKA CORPORATION (JP) | 2012-01-10 | — | — | US | disclosed |
| US-8093378-B2 | Crystallization method for intermediates of carbapenem antibiotics | KANEKA CORPORATION (JP) | 2012-01-10 | — | — | US | disclosed |
| US-20090118496-A1 | Crystallization Method for Intermediates of Carbapenem Antibiotics | KANEKA CORPORATION (JP) | 2009-05-07 | — | — | US | disclosed |
| US-20090118496-A1 | Crystallization Method for Intermediates of Carbapenem Antibiotics | KANEKA CORPORATION (JP) | 2009-05-07 | — | — | US | disclosed |
| EP-2014666-A1 | IMPROVED METHOD FOR THE CRYSTALLIZATION OF INTERMEDIATES OF CARBAPENEM ANTIBIOTICS | Kaneka Corporation (JP) | 2009-01-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118496-A1 | Crystallization Method for Intermediates of Carbapenem Antibiotics | OTUB1, PYCARD, OTUD7B | PLCG1 3317/4885ELANE 3442/4885RAB9A 3963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.